Background: Older people with joint contractures in nursing homes often experience severe restrictions in their activities and participation. The effectiveness of an individually tailored complex intervention to improve residents' activities and participation by incorporating the biopsychosocial perspective into nursing care using a structured facilitator approach could not be established in the JointConEval cluster-randomised controlled trial. This process evaluation aimed to systematically identify factors influencing implementation and effectiveness.
View Article and Find Full Text PDFObjective: This study aims to examine the effects of the individually tailored complex intervention Participation Enabling Care in Nursing (PECAN) on activities and participation of residents with joint contractures.
Design: Multicentre pragmatic cluster-randomised controlled trial.
Setting: 35 nursing homes in Germany (August 2018-February 2020).
Introduction: The small-scale healthcare in Saxony-Anhalt is described as disparate, as regions with good healthcare structures and increasingly undersupplied regions face each other. Deficits in cross-sectoral therapy management jeopardizes ambulatory care after hospital stay in rural areas. This study aims to analyze cross-sectoral care trajectories of patients with colorectal cancer in Saxony-Anhalt over the period from diagnosis up to one year post-discharge and to identify differences in care between patients from urban vs.
View Article and Find Full Text PDFBackground: Joint contractures in frail older people are associated with serious restrictions in participation. We developed the Participation Enabling CAre in Nursing (PECAN) intervention, a complex intervention to enable nurses to promote participation in nursing home residents with joint contractures. The aim of this study was to examine the feasibility of the implementation strategy and to identify enablers and barriers for a successful implementation.
View Article and Find Full Text PDFPurpose: The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.
Patients And Methods: In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week cycles). Patients had progression after ≥ 2 lines of prior therapy and no extramedullary disease.